- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Di | Odonate announces positive top-line results for Tesetaxel in phase 3 metastatic breast cancer trial | ||
| Di | Catalent to expand manufacturing for Covid-19 vaccine candidate AZD1222 | ||
| Di | Exelixis announces submission of sNDA to FDA for CABOMETYX plus Opdivo for advanced RCC | ||
| Di | Bristol Myers Squibb to buy clinical-stage protein engineering firm Forbius | ||
| Mo | Novartis' phase 3 COMBI-i trial fails to meet primary endpoint | ||
| Mo | SAB Biotherapeutics launches SAB-185 phase 1b trial in Covid patients | ||
| Mo | FDA issues EUA for convalescent plasma as potential promising Covid-19 treatment | ||
| Mo | Blackstone to acquire Takeda Consumer Healthcare for $2.3bn | ||
| Fr | AbCellera acquires OrthoMab bispecific platform from Dualogics | ||
| Fr | Pfizer, BioNTech share positive early data on mRNA vaccine candidate BNT162b2 against Covid-19 | ||
| Fr | Novartis gets FDA nod for Kesimpta to treat relapsing multiple sclerosis | ||
| Do | BioLineRx achieves enrolment target in phase 3 GENESIS Trial for planned interim analysis | ||
| Do | J&J to acquire Momenta Pharmaceuticals for $6.5bn | ||
| 19.08. | Imfinzi granted FDA priority review for less-frequent, fixed-dose use | ||
| 19.08. | Lilly, Innovent sign expanded licensing deal worth $1bn for TYVYT | ||
| 19.08. | Agilent to invest $150m for expansion of Frederick production facility in US | ||
| 18.08. | Gilead, Tango expand collaboration on targeted immuno-oncology treatments | ||
| 18.08. | GNI Group announces positive results from study of F351 as therapy for HBV-related liver fibrosis in China | ||
| 18.08. | BOLD-100 significantly outperforms remdesivir head-to-head in SARS-CoV-2 model | ||
| 18.08. | BMS signs $475m deal with Dragonfly Therapeutics for IL-12 programme | ||
| 17.08. | First HBV patient dosed in phase IIa clinical trial of ASC22 | ||
| 17.08. | AstraZeneca closes deal to supply AZD1222 Covid-19 vaccine to EU | ||
| 17.08. | Chugai's Enspryng receives regulatory approval from FDA for neuromyelitis optica spectrum disorder | ||
| 17.08. | Sanofi to buy biopharmaceutical firm Principia Biopharma for $3.68bn | ||
| 14.08. | UNION therapeutics to acquire licence for Covid-19 technologies developed by TFF Pharmaceuticals |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
